Brooks, Moore & Associates, Inc. Organon & Co. Transaction History

Brooks, Moore & Associates, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$10.95 - $17.32 $232,687 - $368,050	-21,250 Reduced 39.94%	31,959 $460,000
Q3 2023 Nov 15, 2023	BUY	$16.59 - $23.77 $33,594 - $48,134	2,025 Added 3.96%	53,209 $924,000
Q2 2023 Aug 15, 2023	BUY	$19.27 - $24.63 $203,009 - $259,477	10,535 Added 25.92%	51,184 $1.07 Million
Q1 2023 May 15, 2023	BUY	$21.42 - $32.08 $296,324 - $443,794	13,834 Added 51.59%	40,649 $956,000
Q4 2022 Feb 03, 2023	BUY	$23.31 - $28.61 $625,057 - $767,177	26,815 New	26,815 $749,000
Q4 2021 Feb 04, 2022	SELL	$28.67 - $37.13 $625,378 - $809,916	-21,813 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$28.63 - $35.64 $8,589 - $10,692	300 Added 1.39%	21,813 $715,000
Q2 2021 Jul 21, 2021	BUY	$28.45 - $38.0 $612,044 - $817,494	21,513 New	21,513 $651,000

786

201M

1.71M

865K

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $4.04B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

Get notified when there are updates to the investment portfolio of Brooks, Moore & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Brooks, Moore & Associates, Inc. with notifications on news.